Many newly diagnosed prostate cancers present as low Gleason score tumors that require
no treatment intervention. Distinguishing the many indolent tumors from the minority of lethal …

Advanced prostate cancer can progress to systemic metastatic tumors, which are generally
androgen insensitive and ultimately lethal. Here, we report a comprehensive genomic …

The remarkable variation in prostate cancer clinical behavior represents an opportunity to
identify and understand molecular features that can be used to stratify patients into clinical …

Prostate cancer is one of the most common types of cancer among Canadian men. Next-
generation sequencing using RNA-Seq provides large amounts of data that may reveal …

BACKGROUND. Commercial gene expression assays are guiding clinical decision making
in patients with prostate cancer, particularly when considering active surveillance. Given …

BACKGROUND: Most personalized cancer care strategies involving DNA sequencing are
highly reliant on acquiring sufficient fresh or frozen tissue. It has been challenging to …

Prostate cancers are highly prevalent in the developed world, with inheritable risk
contributing appreciably to tumour development. Genomic heterogeneity within individual …

With the advent of next-generation sequencing technologies and large whole-exome and
genome studies in prostate and other cancers, our understanding of the landscape of …

Prostate cancer is clinically heterogeneous, ranging from indolent to lethal disease.
Expression profiling previously defined three subtypes of prostate cancer, one (subtype-1) …

The majority of newly diagnosed prostate cancers are slow growing, with a long natural life
history. Yet a subset can metastasize with lethal consequences. We reconstructed the …